PDCD1 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs; immunotherapy) targeting programmed cell death-1 (PD-1) have been recently approved for locally advanced and metastatic non-small cell lung cancer (NSCLC) (3), irrespective of the histologic subtype.